Clinical trials: Healthy Patients
Cognitive Impairment Associated With Schizophrenia
Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)
The primary purpose of this randomized, double-blind, placebo-controlled cross-over study was to record and measure 40 Hz-auditory steady-state response (ASSR) in healthy controls (HC) and participants with mild-to-moderate…
- Trial name
- NCT05136690
- Testing
- Nicotine patch, MK-4334
- Where
- 2 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Volunteers, Rheumatoid Arthritis
A Study to Evaluate Safety and Pharmacokinetics of ZB002 in Healthy Participants and Participants With Rheumatoid Arthritis
This double-blind, randomized, placebo-controlled study will assess the safety and pharmacokinetics of ZB002 in healthy participants and in participants with rheumatoid arthritis (RA). The study consists of 2 parts.
- Trial name
- NCT05638854
- Testing
- ZB002
- Where
- 2 sites in Australia, New Zealand
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Zenas BioPharma (USA), LLC
Diabetes Mellitus, Type 2
A Study of LY3108743 in Healthy Participants and Participants With Type 2 Diabetes
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3108743 in healthy participants and in participants with type 2 diabetes.
- Trial name
- NCT01995656
- Testing
- LY3108743 - Capsule, LY3108743 - Solution
- Where
- Singapore
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Dyslipidemias, Familial Hypercholesterolemia
Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetcs and pharmacodynamics of single- and multiple doses of ARO-ANG3 in healthy adult volunteers and in dyslipidemic patients including familial…
- Conditions
- Dyslipidemias, Familial Hypercholesterolemia, Hypertriglyceridemia
- Trial name
- NCT03747224
- Testing
- ARO-ANG3, sterile normal saline (0.9% NaCl)
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Chronic Renal Insufficiency
An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction
The purpose of the study is to provide pertinent information to enable decisions regarding the developability of LHW090 for use in patients with chronic renal insufficiency, including a comparison of the potential risk-benefit…
- Trial name
- NCT01846468
- Testing
- LHW090
- Where
- 2 sites in United States
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Gout
A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With Gout
The purpose of this study is to: Part A: Evaluate the safety and tolerability of single ascending doses of ALN-XDH in healthy adult participants Part B: Evaluate the safety, tolerability and efficacy of ALN-XDH as monotherapy in…
- Trial name
- NCT05256810
- Testing
- ALN-XDH
- Where
- United Kingdom
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Parkinson Disease, Idiopathic
Clinical Study of HER-096 in Healthy Volunteer Subjects and Patients With Parkinson's Disease
In this clinical study, the safety and tolerability of HER-096 and the way the body interacts with the drug (pharmacokinetics) will be investigated. The clinical study consists of two parts.
- Trial name
- NCT06659562
- Testing
- HER-096
- Where
- Finland
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Herantis Pharma Plc.
Deep Vein Thrombosis Leg, Stroke (in Patients With Atrial Fibrillation)
A Healthy Volunteer Study to Investigate the Blood Concentrations, the Effect on Blood Clotting and the Safety of Multiple Doses of DPOC-4088 Tablets in Different Doses.
A study to investigate the concentrations of a new drug DPOC-4088 in blood, and to study the effect of this drug on blood clotting parameters.
- Trial name
- NCT01647620
- Testing
- DPOC-4088
- Where
- Belgium
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Diakron Pharmaceuticals
Schizophrenia, Alzheimer Disease
Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers
Single site, parallel-group, double-blind trial of low or high dose of BI 409306 to evaluate the ocular and systemic safety and pharmacokinetics during 14 day treatment period in patients with schizophrenia, Alzheimer's disease…
- Trial name
- NCT02392468
- Testing
- BI 409306 25 mg, BI 409306 50 mg
- Where
- 3 sites in United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Heart Failure
A Study of BMS-986224 in Healthy Subjects and Heart Failure Patients With Reduced Ejection Fraction
The purpose of this study is test the safety and tolerability of BMS-986224 and its effects on the body in healthy subjects and subjects with chronic heart failure with reduced ejection fraction
- Trial name
- NCT03281122
- Testing
- BMS-986224
- Where
- 18 sites in Czechia, Netherlands and 3 more
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Long QT Syndrome
Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2).
Part 1: This is a Phase 1b, randomized, double-blind, crossover, dose escalation, placebo-controlled study to evaluate the effect of oral LQT-1213 on dofetilide-induced QTc prolongation in healthy adult subjects.
- Trial name
- NCT05906732
- Testing
- LQT-1213, Dofetilide 250 μg Cap
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Thryv Therapeutics, Inc.
Hepatitis B
Study to Evaluate Induction of HBV Virus Neutralizing Antibodies Using VVX001
The Study will evaluate the effects of VVX001, a novel vaccine for hepatitis B, to elicit a robust protective IgG immune response in vaccine naive subjects in subjects who failed to demonstrate seroconversion after treatment with…
- Trial name
- NCT03625934
- Testing
- VVX001
- Where
- 2 sites in Austria
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Viravaxx AG
Healthy
A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 2
The purpose of this study is to characterize the delayed-type hypersensitivity (DTH) response at the site of Candin intradermal injection in the presence of a targeted immune pathway inhibitor.
- Trial name
- NCT04611971
- Testing
- Benlysta, Candin
- Where
- Belgium
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Healthy Adults
An Adherence Tool to Manage Narcotic -Addicted HIV Patients
The purpose of this study is to develop a cost-effective breath-based medication adherence monitoring system that can monitor whether recovering opiate addicts actually take a specific treatment medication called naltrexone.
- Trial name
- NCT02194764
- Testing
- Naltrexone and 2-butanol, 2-butanol which is encapsulated (size 3 capsule) plus 50 mg of naltrexone (HCl form)
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Xhale Assurance
Hepatitis B, Chronic
Evaluation HEC121120 Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of Study
The Safety, Tolerability, Pharmacokinetics and antiviral activity Study of Anti hepatitis B virus treatment drug HEC121120 in Healthy subjects and in patients with chronic hepatitis B
- Trial name
- NCT04536532
- Testing
- HEC121120 tablets, entecavir tablets
- Where
- China
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Chronic Obstructive Pulmonary Disease
An Efficacy and Safety Profile of Inhaled TV48108 in Healthy Volunteers and COPD Patients
The primary objective of the study is to characterize the safety profile and duration of bronchodilation of a single dose of inhaled TV48108.
- Trial name
- NCT02315144
- Testing
- TV48108
- Where
- 7 sites in United States, Australia and 1 more
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Nausea Post Chemotherapy, Vomiting
Pharmacokinetic and Pharmacodynamic Evaluation of Formulations of Δ9-THC
Study based on the pharmacokinetic, pharmacodynamic, safety and stability evaluation of 3 standardized formulations of THC, to be used in healthy volunteers and post-chemotherapy patients as an adjuvant in the symptomatic…
- Conditions
- Nausea Post Chemotherapy, Vomiting, Cancer Pain, Cancer Related Pain
- Trial name
- NCT05272865
- Testing
- Pharmacokinetic and pharmacodynamic profile of THC oral formulations with Dronabinol as comparator
- Where
- Colombia
- Volunteers
- 334 people, healthy volunteers welcome
- Sponsor
- LaSanta S A S
Healthy Volunteers
Safety and Pharmacokinetics of Smoked Cannabis in Healthy Patients
No actual human data for pharmacokinetics, metabolism, safety, pharmacodynamics, nor efficacy parameters are available for inhaled medical cannabis.
- Trial name
- NCT04314804
- Testing
- PPP001
- Where
- Canada
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Tetra Bio-Pharma
Chronic Hepatitis B
Clinical Study to Evaluate the Safety, Tolerance and Pharmacokinetic Characteristics of Single Administration of HRS-5635 Injection in Chinese Healthy Subjects and the Safety, Tolerance, Pharmacokinetics and Antiviral Effect of Multiple Administration in Patients With Chronic Hepatitis B
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-5635 in healthy adults and chronic hepatitis B. To explore the reasonable dosage of HRS-5635.
- Trial name
- NCT05808374
- Testing
- HRS-5635
- Where
- China
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Chronic Obstructive Pulmonary Disease
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of CHF6297 in Healthy Subjects and Patients With COPD
CHF6297 is a potent and selective inhibitor of human MAP kinase p38 being developed as an anti-inflammatory agent for the treatment of inflammatory airways diseases.
- Trial name
- CHF6297 FIH (NCT02815488)
- Testing
- CHF6297 (Part 1 - SAD), CHF6297 (Part 2 - MAD), CHF6297 (Part 3)
- Where
- 2 sites in United Kingdom
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.